Skip to content

A Clinical Trial Evaluating the Effectiveness and Safety of the PowerMe Midline Catheter in the Chinese Population

A Prospective, Multi-center, Open-label, Randomized, Controlled Non-inferiority Clinical Trial Evaluating the Effectiveness and Safety of the PowerMe Midline Catheter Versus Traditional PIV in the Chinese Population

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04719377
Enrollment
256
Registered
2021-01-22
Start date
2021-01-13
Completion date
2022-01-30
Last updated
2022-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheterization

Keywords

midline, overall performance, indwelling time

Brief summary

This study is designed to evaluate the effectiveness and the safety of the PowerMeTM Midline Catheter in the Chinese population.

Detailed description

This is a prospective, multi-center, open-label, randomized, controlled, non-inferiority clinical trial designed to evaluate the effectiveness and the safety of the PowerMeTM Midline Catheter compared to PIVC in the Chinese population in order to support the product's registration in China.

Interventions

DEVICEcatheter placement

catheter placement

Sponsors

Becton, Dickinson and Company
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

PowerMe Midline

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. ≥18 years of age; 2. Inpatient with a need for intravenous infusion for an expected period of more than 4 days but no more than 28 days; 3. The veins in the upper limbs is suitable for puncture and catheterization of both the investigational device and the control device; 4. Willing to provide written Informed Consent and complete the study per the protocol.

Exclusion criteria

1. Coagulation disorder or active bleeding; 2. Skin injury, infection, or dermatosis at the site to be punctured; 3. History of radiotherapy, thrombosis, or vascular surgery; arteriovenous fistula or phlebitis history at the area and/or vein to be catheterized; 4. History of mental illness; 5. End stage renal disease requires vein protection; 6. Conditions with decreased venous flow in the extremity, such as lymphedema of the arm, etc.; 7. Infusions of vesicant or irritant drugs, hyperosmotic infusate (the osmotic pressure \>900mOsm/L in this study), parenteral nutrition, etc., which are not suitable for peripheral intravenous infusion (If other appropriate venous access is established for the aforementioned infusates, the patient may be enrolled). 8. The evaluation of the upper limb veins is Grade II, the evaluation grade is as following: * 0 Veins are obviously bulged on the skin surface. The veins are touchable, thick, straight, soft, elastic and fixed. * I Veins are relatively full and faintly touchable. The veins are less elastic or slide easily. * II Veins are not full or collapsed and untouchable. The veins are hard or sliding. Phlebitis. 9. Self-reported being pregnant or lactating; 10. Other conditions that the investigator considers improper for the study; 11. Participating in another study or already enrolled.

Design outcomes

Primary

MeasureTime frameDescription
Acceptance of the overall performance of the IV catheter systemup to 28 daysAfter the placement of the IV catheter system, the study nurse shall answer yes/no to the following questions: 1. Can the IV catheter system vent the air properly; 2. Can the IV catheter system be inserted and be placed in the blood vessel; 3. Can the needle tube be withdrawn from the septum; After the removal of the IV catheter system, the study nurse shall answer yes/no to the following questions: 4. Can the IV catheter system be removed properly; 5. There is no leakage during the application of the IV catheter system (including the processes of venting, infusion, flushing and sealing, and indwelling).

Secondary

MeasureTime frameDescription
Indwelling timeup to 28 daysThe retention time of the IV catheter system of each subject after successful insertion.
Rate of good performance of the pinch clampup to 28 daysIf the pinch clamp can close and open the tubing properly, performance of the pinch clamp can be evaluated as good.
Incidence of catheter blockageup to 28 daysThe catheter system is blocked, causing the system to fail to infuse the fluid after it is connected to the infusion set/syringe.
Success rate of the first insertion of the catheterFirst day, during catheter insertionSuccessful first insertion means the IV catheter system can be successfully inserted into the blood vessel on the first insertion.
Incidence of phlebitisup to 28 daysIncidence of phlebitis
Incidence of adverse eventsup to 28 daysIncidence of adverse events
Incidence of serious adverse eventsup to 28 daysIncidence of serious adverse events
Incidence of accidental dislodgementup to 28 daysUnintentional premature removal of the catheter from the vessel.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026